Triheptanoin protects motor neurons and delays the onset of motor symptoms in a mouse model of amyotrophic lateral sclerosis

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Tefera, Tesfaye W ^a   Wong, Yide ^a,c   Barkl Luke, Mallory E ^a   Ngo, Shyuan T ^a,b   Thomas, Nicola K ^a   McDonald, Tanya S ^a   Borges, Karin ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; COPPER ZINC SUPEROXIDE DISMUTASE; MESSENGER RNA; METHYLMALONYL COENZYME A MUTASE; PYRUVIC ACID; SUCCINATE DEHYDROGENASE; TRIHEPTANOIN; ALANINE AMINOTRANSFERASE; TRIACYLGLYCEROL;

2 OXOGLUTARATE GENE; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GASTROCNEMIUS MUSCLE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GRIP STRENGTH; MALE; METHYLMALONYL COA MUTASE GENE; MOTONEURON; MOTOR DYSFUNCTION; MOUSE; MUSCLE METABOLISM; NEUROPROTECTION; NONHUMAN; PYRUVATE GENE; SOD1 GENE; SUCCINATE DEHYDROGENASE GENE; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CITRIC ACID CYCLE; DRUG EFFECTS; GENETICS; HAND STRENGTH; METABOLISM; MUTANT MOUSE STRAIN; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALANINE TRANSAMINASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CITRIC ACID CYCLE; FEMALE; HAND STRENGTH; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MOTOR NEURONS; SUCCINATE DEHYDROGENASE; SUPEROXIDE DISMUTASE-1; TRIGLYCERIDES; WEIGHT LOSS;

EID: 84991238742     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161816     Document Type: Article

References (92)

1. Baumer D, Talbot K, Turner MR (2014) Advances in motor neurone disease. Journal of the Royal Society of Medicine 107: 14-21. Doi: 10.1177/0141076813511451 PMID: 24399773
2. Cleveland DW, Rothstein JD (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nature reviews Neuroscience 2: 806-819. PMID: 11715057
3. Chen S, Sayana P, Zhang X, LeW(2013) Genetics of amyotrophic lateral sclerosis: an update. Molecular neurodegeneration 8: 28. Doi: 10.1186/1750-1326-8-28 PMID: 23941283
4. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62 PMID: 8446170
5. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature genetics 40: 572-574. Doi: 10.1038/ng.132 PMID: 18372902
6. Kwiatkowski TJ Jr., Bosco DA, Leclerc AL, Tamrazian, Vanderburg CR, Russ C, et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323: 1205-1208. Doi: 10.1126/science.1166066 PMID: 19251627
7. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al. (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477: 211-215. Doi: 10.1038/nature10353 PMID: 21857683
8. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72: 245-256. Doi: 10.1016/j.neuron.2011.09.011 PMID: 21944778
9. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72: 257-268. Doi: 10.1016/j.neuron.2011.09.010 PMID: 21944779
10. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. (2011) Amyotrophic lateral sclerosis. Lancet 377: 942-955. Doi: 10.1016/S0140-6736(10)61156-7 PMID: 21296405
11. Milani P, Gagliardi S, Cova E, Cereda C (2011) SOD1 Transcriptional and Posttranscriptional Regulation and Its Potential Implications in ALS. Neurol Res Int 2011: 458427. Doi: 10.1155/2011/458427 PMID: 21603028
12. Cozzolino M, Carri MT (2012) Mitochondrial dysfunction in ALS. Prog Neurobiol 97: 54-66. Doi: 10. 1016/j.pneurobio.2011.06.003 PMID: 21827820
13. Turner BJ, Talbot K (2008) Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 85: 94-134. Doi: 10.1016/j.pneurobio.2008.01.001 PMID: 18282652
14. Vucic S, Kiernan MC (2009) Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med 9: 255-272. PMID: 19355908
15. Shi P, Wei Y, Zhang J, Gal J, Zhu H (2010) Mitochondrial dysfunction is a converging point of multiple pathological pathways in amyotrophic lateral sclerosis. J Alzheimers Dis 20 Suppl 2: S311-324. Doi: 10.3233/JAD-2010-100366 PMID: 20463400
16. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ (2011) Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nature reviews Neurology 7: 616-630. Doi: 10.1038/nrneurol. 2011.152 PMID: 22051914
17. Barber SC, Mead RJ, Shaw PJ (2006) Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochimica et biophysica acta 1762: 1051-1067. PMID: 16713195
18. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, et al. (1990) Abnormal excitatory amino acidmetabolism in amyotrophic lateral sclerosis. Annals of neurology 28: 18-25. PMID: 2375630
19. McGeer PL, McGeer EG (2002) Inflammatory processes in amyotrophic lateral sclerosis. Muscle & nerve 26: 459-470.
20. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, et al. (1998) Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281: 1851-1854. PMID: 9743498
21. Julien JP, Beaulieu JM (2000) Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? Journal of the neurological sciences 180: 7-14. PMID: 11090858
22. Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loeffler JP (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proceedings of the National Academy of Sciences of the United States of America 101: 11159-11164. PMID: 15263088
23. Dupuis L, Pradat PF, Ludolph AC, Loeffler JP (2011) Energy metabolism in amyotrophic lateral sclerosis. The Lancet Neurology 10: 75-82. Doi: 10.1016/S1474-4422(10)70224-6 PMID: 21035400
24. Vielhaber S, Kunz D, Winkler K, Wiedemann FR, Kirches E, Feistner H, et al. (2000) Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 123 (Pt 7): 1339-1348. PMID: 10869047
25. Crugnola V, Lamperti C, Lucchini V, Ronchi D, Peverelli L, Prelle A, et al. (2010) Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Archives of neurology 67: 849-854. Doi: 10.1001/archneurol.2010.128 PMID: 20625092
26. Kong J, Xu Z (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. Journal of Neuroscience 18: 3241-3250. PMID: 9547233
27. Sasaki S, Iwata M (1996) Ultrastructural study of synapses in the anterior horn neurons of patients with amyotrophic lateral sclerosis. Neuroscience letters 204: 53-56. PMID: 8929976
28. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, et al. (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105-1116. PMID: 7605627
29. Vielhaber S, Winkler K, Kirches E, Kunz D, Buchner M, Feistner H, et al. (1999) Visualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosis. Journal of the neurological sciences 169: 133-139. PMID: 10540022
30. Wiedemann FR, Winkler K, Kuznetsov AV, Bartels C, Vielhaber S, Feistner H, et al. (1998) Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. Journal of the neurological sciences 156: 65-72. PMID: 9559989
31. Luo G, Yi J, Ma C, Xiao Y, Yi F, Yu T, et al. (2013) Defective mitochondrial dynamics is an early event in skeletal muscle of an amyotrophic lateral sclerosis mouse model. PloS one 8: e82112. Doi: 10.1371/journal.pone.0082112 PMID: 24324755
32. Russell AP, Wada S, Vergani L, Hock MB, Lamon S, Leger B, et al. (2013) Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiology of disease 49: 107-117. Doi: 10.1016/j.nbd.2012.08.015 PMID: 22975021
33. Echaniz-Laguna A, Zoll J, Ponsot E, N'Guessan B, Tranchant C, Loeffler JP, et al. (2006) Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: a temporal study in man. Experimental neurology 198: 25-30. PMID: 16126198
34. Mattiazzi M, D'Aurelio M, Gajewski CD, Martushova K, Kiaei M, Beal MF, et al. (2002) Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. The Journal of biological chemistry 277: 29626-29633. PMID: 12050154
35. Dupuis L, di Scala F, Rene F, de Tapia M, Oudart H, Pradat PF, et al. (2003) Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB J 17: 2091-2093. PMID: 14500553
36. Derave W, Van Den Bosch L, Lemmens G, Eijnde BO, Robberecht W, Hespel P (2003) Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiology of disease 13: 264-272. PMID: 12901841
37. Browne SE, Bowling AC, Baik MJ, Gurney M, Brown RH Jr, Beal MF (1998) Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. Journal of neurochemistry 71: 281-287. PMID: 9648876
38. Dalakas MC, Hatazawa J, Brooks RA, Di Chiro G (1987) Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Annals of neurology 22: 580-586. PMID: 3501273
39. Hatazawa J, Brooks RA, Dalakas MC, Mansi L, Di Chiro G (1988) Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study. Journal of computer assisted tomography 12: 630-636. PMID: 3260610
40. Ludolph AC, Langen KJ, Regard M, Herzog H, Kemper B, Kuwert T, et al. (1992) Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta neurologica Scandinavica 85: 81-89. PMID: 1574993
41. Cistaro A, Valentini MC, Chio A, Nobili F, Calvo A, Moglia C, et al. (2012) Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. European journal of nuclear medicine and molecular imaging 39: 251-259. Doi: 10.1007/s00259-011-1979-6 PMID: 22089661
42. Pagani M, Chio A, Valentini MC, Oberg J, Nobili F, Calvo A, et al. (2014) Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology 83: 1067-1074. Doi: 10.1212/WNL. 0000000000000792 PMID: 25122207
43. Miyazaki K, Masamoto K, Morimoto N, Kurata T, Mimoto T, Obata T, et al. (2012) Early and progressive impairment of spinal blood flow-glucose metabolism coupling in motor neuron degeneration of ALS model mice. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 32: 456-467.
44. Smittkamp SE, Morris JK, Bomhoff GL, Chertoff ME, Geiger PC, Stanford JA (2014) SOD1-G93A mice exhibit muscle-fiber-type-specific decreases in glucose uptake in the absence of whole-body changes in metabolism. Neuro-degenerative diseases 13: 29-37. Doi: 10.1159/000351606 PMID: 24021858
45. Raman R, Allen SP, Goodall EF, Kramer S, Ponger LL, Heath PR, et al. (2015) Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions. Neuropathology and applied neurobiology 41: 201-226. Doi: 10.1111/nan. 12147 PMID: 24750211
46. Lederer CW, Torrisi A, Pantelidou M, Santama N, Cavallaro S (2007) Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC genomics 8: 26. PMID: 17244347
47. Wang XS, Simmons Z, Liu W, Boyer PJ, Connor JR (2006) Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. Amyotrophic lateral sclerosis: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 7: 201-210.
48. Saris CG, Groen EJ, van Vught PW, van Es MA, Blauw HM, Veldink JH, et al. (2013) Gene expression profile of SOD1-G93A mouse spinal cord, blood and muscle. Amyotrophic lateral sclerosis & frontotemporal degeneration 14: 190-198.
49. Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig-Grosch S, Henriques A, et al. (2015) A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med 7: 526-546. Doi: 10.15252/emmm.201404433 PMID: 25820275
50. Choi JK, Kustermann E, Dedeoglu A, Jenkins BG (2009) Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. The European journal of neuroscience 30: 2143-2150. Doi: 10.1111/j.1460-9568.2009.07015.x PMID: 19930399
51. Niessen HG, Debska-Vielhaber G, Sander K, Angenstein F, Ludolph AC, Hilfert L, et al. (2007) Metabolic progression markers of neurodegeneration in the transgenic G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 25: 1669-1677. PMID: 17432958
52. D'Alessandro G, Calcagno E, Tartari S, Rizzardini M, Invernizzi RW, Cantoni L (2011) Glutamate and glutathione interplay in a motor neuronal model of amyotrophic lateral sclerosis reveals altered energy metabolism. Neurobiol Dis 43: 346-355. Doi: 10.1016/j.nbd.2011.04.003 PMID: 21530659
53. Brunengraber H, Roe CR (2006) Anaplerotic molecules: Current and future. J Inherit Metab Dis 29: 327-331. PMID: 16763895
54. Roe CR, Mochel F (2006) Anaplerotic diet therapy in inherited metabolic disease: Therapeutic potential. J Inherit Metab Dis 29: 332-340. PMID: 16763896
55. Adanyeguh IM, Rinaldi D, Henry PG, Caillet S, Valabregue R, Durr A, et al. (2015) Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology 84: 490-495. Doi: 10.1212/WNL.0000000000001214 PMID: 25568297
56. Pascual JM, Liu P, Mao D, Kelly DI, Hernandez A, Sheng M, et al. (2014) Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement. JAMA Neurol 71: 1255-1265. Doi: 10.1001/jamaneurol.2014.1584 PMID: 25110966
57. Corbett A, Garg N, Crosbie A, Borges K (2015) A Pilot Study of Triheptanoin Treatment in Sporadic Inclusion Body Myositis (sIBM). Annals of Neurology 78: S102.
58. Gu L, Zhang GF, Kombu RS, Allen F, Kutz G, Brewer WU, et al. (2010) Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. II. Effects on lipolysis, glucose production, and liver acyl-CoA profile. Am J Physiol Endocrinol Metab 298: E362-371. Doi: 10.1152/ajpendo.00384.2009 PMID: 19903863
59. Marin-Valencia I, Good LB, Ma Q, Malloy CR, Pascual JM (2013) Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain. J Cereb Blood Flow Metab 33: 175-182. Doi: 10.1038/jcbfm.2012.151 PMID: 23072752
60. Hadera MG, Smeland OB, McDonald TS, Tan KN, Sonnewald U, Borges K (2014) Triheptanoin partially restores levels of tricarboxylic acid cycle intermediates in the mouse pilocarpine model of epilepsy. J Neurochem 129: 107-119. Doi: 10.1111/jnc.12610 PMID: 24236946
61. Borges K, Sonnewald U (2012) Triheptanoin-a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment? Epilepsy Res 100: 239-244. Doi: 10.1016/j.eplepsyres. 2011.05.023 PMID: 21855298
62. Mochel F, Duteil S, Marelli C, Jauffret C, Barles A, Holm J, et al. (2010) Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease. Eur J Hum Genet 18: 1057-1060. Doi: 10.1038/ejhg.2010.72 PMID: 20512158
63. Willis S, Stoll J, Sweetman L, Borges K (2010) Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models. Neurobiol Dis 40: 565-572. Doi: 10.1016/j.nbd.2010.07.017 PMID: 20691264
64. Schwarzkopf TM, Koch K, Klein J (2015) Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin. Neuroscience 300: 201-209. Doi: 10.1016/j.neuroscience.2015.05.014 PMID: 25982559
65. Francis JS, Markov V, Leone P (2014) Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease. J Inherit Metab Dis 37: 369-381. Doi: 10.1007/s10545-013-9663-6 PMID: 24288037
66. Thomas NK, Willis S, Sweetman L, Borges K (2012) Triheptanoin in acute mouse seizure models. Epilepsy Res 99: 312-317. Doi: 10.1016/j.eplepsyres.2011.12.013 PMID: 22260920
67. Ngo ST, Baumann F, Ridall PG, Pettitt AN, Henderson RD, Bellingham MC, et al. (2012) The relationship between Bayesian motor unit number estimation and histological measurements of motor neurons in wild-type and SOD1(G93A) mice. Clin Neurophysiol 123: 2080-2091. Doi: 10.1016/j.clinph.2012.01. 028 PMID: 22521362
68. Coggeshall RE, Lekan HA (1996) Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J Comp Neurol 364: 6-15. PMID: 8789272
69. Gill A, Kidd J, Vieira F, Thompson K, Perrin S (2009) No benefit from chronic lithium dosing in a siblingmatched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One 4: e6489. Doi: 10.1371/journal.pone.0006489 PMID: 19649300
70. Lee JD, Kamaruzaman NA, Fung JN, Taylor SM, Turner BJ, Atkin JD, et al. (2013) Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 10: 119. Doi: 10.1186/1742-2094-10-119 PMID: 24067070
71. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034. PMID: 12184808
72. Lai JCK, Cooper AJL (1986) Brain α-Ketoglutarate Dehydrogenase Complex: Kinetic Properties, Regional Distribution, and Effects of Inhibitors. J Neurochem 47: 1376-1386. PMID: 3760866
73. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, et al. (2010) Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler 11: 38-45. Doi: 10.3109/17482960903545334 PMID: 20184514
74. Steyn FJ, Ngo ST, Lee JD, Leong JW, Buckley AJ, Veldhuis JD, et al. (2012) Impairments to the GHIGF-I axis in hSOD1G93A mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis. Endocrinology 153: 3735-3746. Doi: 10.1210/en.2011-2171 PMID: 22621959
75. Aso E, Semakova J, Joda L, Semak V, Halbaut L, Calpena A, et al. (2013) Triheptanoin supplementation to ketogenic diet curbs cognitive impairment in APP/PS1 mice used as a model of familial Alzheimer's disease. Curr Alzheimer Res 10: 290-297. PMID: 23131121
76. Roe CR, Bottiglieri T, Wallace M, Arning E, Martin A (2010) Adult Polyglucosan Body Disease (APBD): Anaplerotic diet therapy (Triheptanoin) and demonstration of defective methylation pathways. Mol Genet Metab 101: 246-252. Doi: 10.1016/j.ymgme.2010.06.017 PMID: 20655781
77. Roe CR, Yang BZ, Brunengraber H, Roe DS, Wallace M, Garritson BK (2008) Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 71: 260-264. Doi: 10.1212/01.wnl. 0000318283.42961.e9 PMID: 18645163
78. Camilleri M, Balm RK, Low PA (1993) Autonomic dysfunction in patients with chronic intestinal pseudoobstruction. Clin Auton Res 3: 95-100. PMID: 8324379
79. Toepfer M, Folwaczny C, Klauser A, Riepl RL, Muller-Felber W, Pongratz D (1999) Gastrointestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1: 15-19. PMID: 12365061
80. Vadakkadath Meethal S, Atwood CS (2012) Lactate dyscrasia: a novel explanation for amyotrophic lateral sclerosis. Neurobiol Aging 33: 569-581. Doi: 10.1016/j.neurobiolaging.2010.04.012 PMID: 20541840
81. Barber SC, Shaw PJ (2010) Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 48: 629-641. Doi: 10.1016/j.freeradbiomed.2009.11.018 PMID: 19969067
82. Andersson U, Leighton B, Young ME, Blomstrand E, Newsholme EA (1998) Inactivation of aconitase and oxoglutarate dehydrogenase in skeletal muscle in vitro by superoxide anions and/or nitric oxide. Biochem Biophys Res Commun 249: 512-516. PMID: 9712727
83. Tretter L, Adam-Vizi V (2000) Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci 20: 8972-8979. PMID: 11124972
84. Bach AC, Babayan VK (1982) Medium-chain triglycerides: an update. Am J Clin Nutr 36: 950-962. PMID: 6814231
85. Bough KJ, Rho JM (2007) Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 48: 43-58. PMID: 17241207
86. Zhao Z, Lange DJ, Voustianiouk A, MacGrogan D, Ho L, Suh J, et al. (2006) A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC neuroscience 7: 29. PMID: 16584562
87. Zhao W, Varghese M, Vempati P, Dzhun A, Cheng A, Wang J, et al. (2012) Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. PloS one 7: e49191. Doi: 10.1371/journal.pone.0049191 PMID: 23145119
88. McDonald TS, Tan KN, Hodson MP, Borges K (2014) Alterations of hippocampal glucose metabolism by even versus uneven medium chain triglycerides. J Cereb Blood Flow Metab 34: 153-160. Doi: 10. 1038/jcbfm.2013.184 PMID: 24169853
89. Ngo ST, Steyn FJ (2015) The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis. Cell Regen (Lond) 4: 5.
90. Miquel E, Cassina A, Martinez-Palma L, Bolatto C, Trias E, Gandelman M, et al. (2012) Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PloS one 7: e34776. Doi: 10.1371/journal.pone.0034776 PMID: 22509356
91. ALS Untangled Group (2013) ALS Untangled No. 20: the Deanna protocol. Amyotroph Lateral Scler Frontotemporal Degener 14: 319-323. Doi: 10.3109/21678421.2013.788405 PMID: 23638638
92. Ari C, Poff AM, Held HE, Landon CS, Goldhagen CR, Mavromates N, et al. (2014) Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model. PLoS One 9: e103526. Doi: 10.1371/journal.pone.0103526 PMID: 25061944